Head & Shoulders Sells Skincare Claims on a 1.8% Drug
Head & Shoulders announced its Scalp Care Collection on October 15, 2026, fronted by niacinamide, bio-ceramides and a proprietary HydraSC+ Complex. That complex is built on 1.8 percent salicylic acid or 1 percent zinc pyrithione. In the United States both are over-the-counter drug actives, and 1.8 percent is the exact floor of the range the federal monograph permits. The vocabulary of the launch is skincare. The chemistry is a drug, and a drug label is a closed list of sentences.
What is actually inside the HydraSC+ Complex?
Two ingredients that have been in dandruff products for decades. Zinc pyrithione, which the company's announcement describes as targeting Malassezia, the scalp microbe associated with dandruff, and salicylic acid, which lifts flakes and buildup by exfoliating. The announcement gives one concentration for each: 1 percent and 1.8 percent. It gives no concentration for niacinamide or for the bio-ceramides, the two ingredients the collection is named after.
The collection runs across three regimens. Scalp Soothe with niacinamide covers a cooling shampoo and a cooling scalp spray, aimed at itch. Scalp Purify with salicylic acid covers a clarifying pre-shampoo and a volumizing shampoo, aimed at oil. Scalp Restore with bio-ceramides covers a nourishing shampoo, conditioner and leave-on serum, sulfate-free, aimed at dryness. The announcement names salicylic acid for the Purify regimen and does not say which regimens carry the zinc pyrithione.
Why does that chemistry make this a drug rather than a cosmetic?
Because in the United States the ingredient determines the category. A cosmetic cleanses or beautifies; a drug is intended to treat or prevent a condition. Dandruff is a condition, and the Food and Drug Administration lists the ingredients that can be used against it in 21 CFR 358.710: coal tar at 0.5 to 5 percent, pyrithione zinc at 0.3 to 2 percent in products washed off after brief exposure, salicylic acid at 1.8 to 3 percent, selenium sulfide at 1 percent, sulfur at 2 to 5 percent.
A product built on those actives is an over-the-counter drug, registered and labeled as one. Head & Shoulders already files this way. A current Head & Shoulders shampoo listed with the FDA shows pyrithione zinc 1 percent as its active ingredient, the purpose line "Anti-dandruff," the use "fights recurrence of the symptoms of dandruff," the marketing category "OTC Monograph Drug" under monograph M032, and The Procter & Gamble Manufacturing Company as labeler. Those bottles carry a Drug Facts panel, not an ingredient list.
The placement of 1.8 percent is worth pausing on. The monograph range for salicylic acid runs 1.8 to 3 percent, so the formula sits on the lowest concentration at which the claim is available at all. The 1 percent zinc pyrithione sits in the lower half of its wash-off range of 0.3 to 2 percent, and just above the 0.95 percent floor the monograph sets for seborrheic dermatitis.
What is the label allowed to say?
Very little, and the wording is prescribed. Under 21 CFR 358.750, the indications statement must read "For relief of" or "Controls" plus "the symptoms of" plus dandruff, seborrheic dermatitis or psoriasis. The regulation permits a short list of substitutions: "fights," "reduces," "helps eliminate," "helps stop," "controls recurrence of," "helps prevent recurrence of." In place of "the symptoms of" a label can name skin or scalp plus itching, irritation, redness, flaking or scaling, followed by "associated with." Other statements are permitted only where they describe indications already established in that list.
That is the entire vocabulary of an anti-dandruff drug claim in the United States. It has no room for barrier repair, no room for moisture duration, and no room for volume.
Where do the launch claims live, then?
Outside it. The announcement says the Purify regimen instantly removes up to 99 percent of flakes, oil and buildup and delivers up to 5 times more volume. It says the Restore regimen provides a 72-hour moisture lock and restores the scalp barrier. It says the Soothe regimen delivers instant cooling and itch relief from first use and adds shine. Flaking and itching are monograph territory. Oil, buildup, volume, moisture duration, barrier restoration and shine are not.
Those are cosmetic claims riding on a drug product, which is a legitimate and common structure. It also explains the shape of the launch. The drug layer is frozen: every competitor using the same actives can make the same anti-dandruff statement in the same words, and no amount of formulation changes that. Differentiation has to happen in the layer the monograph does not reach, which is exactly where niacinamide, bio-ceramides and the word scalp sit.
What does the leave-on format change?
The arithmetic. The monograph treats a product left on the skin or scalp as a different product from one rinsed off after brief exposure, and it caps leave-on pyrithione zinc at 0.1 to 0.25 percent against 0.3 to 2 percent for wash-off. The gap is roughly eightfold at the top, and it exists because exposure time, not concentration alone, determines dose.
The collection includes two leave-on formats: a cooling scalp spray the announcement says can be used up to four times daily between washes, and a nourishing leave-on serum. The announcement does not state whether either contains a monograph active. If they do, they sit under the leave-on ceiling rather than the wash-off one. If they do not, they are cosmetics sold alongside drugs in the same regimen, which is a labeling and claim question rather than a safety one.
What happens to the same formula outside the United States?
It changes legal identity twice. In Korea, zinc pyrithione is a restricted cosmetic ingredient under the cosmetic safety standards rather than a drug active. It is permitted at 0.5 percent as a preservative in rinse-off products, and at a total of 1.0 percent in rinse-off anti-dandruff and anti-itch products such as shampoos and rinses and in products for relief of hair-loss symptoms. It is prohibited in everything else. A 1 percent wash-off formula is therefore legal in Korea at its ceiling, and it is a cosmetic there, not a drug.
Salicylic acid runs the same way. Korea permits 0.5 percent as a preservative, 2 percent in body cleansing products and 3 percent in rinse-off hair products, restricting non-preservative use to functional cosmetic active ingredients, and prohibiting it in products specified for infants or children aged 13 and under, with shampoo excepted.
In the European Union, zinc pyrithione is not permitted in cosmetics at any concentration. Regulation (EU) 2021/1902 of November 3, 2021 moved it to the prohibited list with effect from March 1, 2022, following a reproductive toxicity category 1B classification. The Scientific Committee on Consumer Safety found in March 2020 that shampoo containing under 1 percent was safe, but a CMR substance stays banned unless it is also shown to be irreplaceable, and that was not demonstrated. Before the ban it had been allowed at up to 1 percent in rinse-off products as a preservative.
One molecule, three regulatory identities: a drug active in the United States, a capped cosmetic ingredient in Korea, and a banned substance in Europe. A global scalp care platform built on it is three different product development programs wearing one brand name.
Which statements here are regulatory facts and which belong to the company?
The concentration limits, the permitted wordings and the EU prohibition are published law. Almost everything else in the announcement is the company's own.
The flake-removal claim is described as clinically proven, and the announcement names no study, sample size or method. The brand is described as the world's number one anti-dandruff shampoo and the number one United States dermatologist recommended anti-dandruff brand, both company statements. The most-awarded scalp care brand claim carries a footnote defining its own universe: total awards from United States beauty, grooming and lifestyle publications and websites within the Nielsen scalp-care segment between 2017 and 2026. Matt Krehbiel, vice president for Head & Shoulders, said the launch marks a bold new chapter for the brand and that exceptional hair starts at the scalp.
What does US$11.99 ask of a mass shelf?
Shampoos and conditioners carry a suggested price of US$11.99, available at Walmart, with treatments and wider distribution following in November 2026. That price asks a mass drugstore and supercenter shopper to pay a prestige-adjacent figure for a product in the aisle where dandruff shampoo has been a value purchase for decades.
The category data makes that a reasonable bet and an exposed one. United States mass beauty grew 7 percent in the first half of 2026 to US$39.2 billion, according to Circana, with mass hair care also up 7 percent in dollars while units dipped, meaning price rather than volume carried the growth. Prestige hair care grew 11 percent in dollars on 8 percent unit growth over the same period. A mass brand raising its price point is following where the dollars went. It is also testing whether a shopper who has been trained for decades to buy this product on price will re-evaluate it on vocabulary.
What does the rest of the industry take from this?
Three positions read the same filing differently.
Manufacturers and formulators. A scalp platform that travels internationally cannot be one formula. The actives that define the category in the United States are capped at a different level in Korea and unavailable in Europe, which means separate formulas, separate substantiation files and separate claim sets per region. The branding is global; the chemistry is not.
Brands and buyers. When the drug layer is a fixed and shared vocabulary, competitive advantage has to be built in the cosmetic layer around it. That is a marketing and substantiation contest rather than a formulation one, and it is winnable by companies with no monograph expertise at all.
Regulators and investors. A product that reads as skincare and files as a drug sits under two claim regimes at once. The monograph claim is protected and inflexible. Everything stacked on top is an ordinary cosmetic claim, enforceable as advertising, and it is where the entire repositioning rests.
The actives did not change. The sentences around them did. In this category the sentences are the product development.
Comments